search
Back to results

The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope

Primary Purpose

Syncope, Vasovagal

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
CPC - Capsaicin, Phenylephrine, Caffeine
Tilt Table Test
Placebo
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Syncope, Vasovagal focused on measuring Neurocardiogenic Syncope, Reflex Syncope, Fainting Spells

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Established diagnosis of typical vasovagal syncope
  2. Age 18-50 years

Exclusion Criteria:

  1. Systolic BP >130 mmHg
  2. History of hypertension or cardiac arrhythmias
  3. History of cardiovascular disease or cerebral ischemic events
  4. Allergic reaction to any of the drug components
  5. Contraindication to tilt testing
  6. Any physical or psychological symptom, based on the clinical judgment of the investigators that would make a participant unsuitable for the study
  7. Any use of a medication(s) based on the clinical judgment of the investigators that would make a participant unsuitable for the study (e.g. fludrocortisone, theophylline, prazosin, doxazosin, terazosin, MAO-inhibitors, pseudoephedrine, decongestant and PDE5 inhibitors).
  8. Unwilling to discontinue Midodrine or beta-blocker therapy 48 hours before tilt table testing.
  9. Women who are pregnant (confirmed with pregnancy test on day of study) or lactating.

Sites / Locations

  • University of Wisconsin- Madsion

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

CPC Adminstration

Placebo Adminstration

Arm Description

Single dose of CPC will be given during tilt table test

Single dose of Placebo will be given during tilt table test

Outcomes

Primary Outcome Measures

Percentage of participants who have hypotensive syncope or near syncope with SBP less than or equal to 70 mmHG during tilt test
Hypotensive syncope is defined as transient loss of consciousness associated with SBP less than or equal to 90 mmHg. Near syncope is defined as sensation of "near fainting" while still being responsive to verbal commands. Near syncope will be used as a primary endpoint only when it is associated with a SBP less than or equal to 70 mmHg.

Secondary Outcome Measures

Time to syncope or near-syncope after CPC or placebo administration
Time in minutes
Percentage of patients who have asystolic pauses > 3 sec in the CPC and placebo arms
Asystole will be defined as absence of QRS complexes
Fatigue Score at 1, 4, and 8 hours post tilt table testing
Self report of fatigue on a 1-5 scale where higher numbers indicate increased fatigue

Full Information

First Posted
July 12, 2021
Last Updated
September 27, 2023
Sponsor
University of Wisconsin, Madison
search

1. Study Identification

Unique Protocol Identification Number
NCT04972123
Brief Title
The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Official Title
The Effect of Capsaicin-Phenylephrine-Caffeine Formulation on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
July 20, 2021 (Actual)
Primary Completion Date
August 25, 2023 (Actual)
Study Completion Date
August 31, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Syncope is defined as transient loss of consciousness associated with inability to maintain postural tone with rapid and spontaneous recovery. The purpose of this study is to assess the effects of sublingual administration of a new medication called CPC on tilt-induced syncope in patients with a history of vasovagal syncope (VVS) or near syncope. 140 participants were randomized at the University of Wisconsin - Madison. Each participant will be in the study for 1 day.
Detailed Description
Vasovagal syncope (VVS) is the most common type of syncope. The mechanism is reflex-mediated triggered by various afferent input to the brain. The event is usually preceded by diaphoresis, warmth, nausea, and pallor, and is followed by fatigue. While several drugs are indicated in the treatment of VVS, to our knowledge, there is no current treatment of an impending syncopal attack. In the present study, the investigators hypothesize that a single administration of sublingual CPC preparation during the prodromal phase aborts tilt-induced syncope or near syncope with SBP less than or equal to 70 mmHg in patients with a history of VVS. Patients with an established diagnosis of typical VVS or near syncope will be randomized to receive CPC or placebo in 1:1 ratio. Drug or placebo will be administered at the onset of prodromes during tilt table testing. In addition to the primary endpoint (syncope or near syncope with SBP less than or equal to 70 mmHg), the investigators will be assessing the effects of the drug on time to event, incidence of asystole (> 3 sec), and fatigue after tilt table testing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Syncope, Vasovagal
Keywords
Neurocardiogenic Syncope, Reflex Syncope, Fainting Spells

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Randomized 1:1 to CPC or placebo
Allocation
Randomized
Enrollment
140 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CPC Adminstration
Arm Type
Experimental
Arm Description
Single dose of CPC will be given during tilt table test
Arm Title
Placebo Adminstration
Arm Type
Placebo Comparator
Arm Description
Single dose of Placebo will be given during tilt table test
Intervention Type
Drug
Intervention Name(s)
CPC - Capsaicin, Phenylephrine, Caffeine
Intervention Description
CPC is a combination of Capsaicin, Phenylephrine and Caffeine
Intervention Type
Diagnostic Test
Intervention Name(s)
Tilt Table Test
Intervention Description
Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo for CPC
Primary Outcome Measure Information:
Title
Percentage of participants who have hypotensive syncope or near syncope with SBP less than or equal to 70 mmHG during tilt test
Description
Hypotensive syncope is defined as transient loss of consciousness associated with SBP less than or equal to 90 mmHg. Near syncope is defined as sensation of "near fainting" while still being responsive to verbal commands. Near syncope will be used as a primary endpoint only when it is associated with a SBP less than or equal to 70 mmHg.
Time Frame
During tilt table testing (up 35 minutes)
Secondary Outcome Measure Information:
Title
Time to syncope or near-syncope after CPC or placebo administration
Description
Time in minutes
Time Frame
During tilt table testing (up 35 minutes)
Title
Percentage of patients who have asystolic pauses > 3 sec in the CPC and placebo arms
Description
Asystole will be defined as absence of QRS complexes
Time Frame
During tilt table testing (up 35 minutes)
Title
Fatigue Score at 1, 4, and 8 hours post tilt table testing
Description
Self report of fatigue on a 1-5 scale where higher numbers indicate increased fatigue
Time Frame
Up to 8 hours after tilt table testing

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Established diagnosis of typical vasovagal syncope or near syncope Age 18-50 years Exclusion Criteria: Systolic BP >130 mmHg History of hypertension or cardiac arrhythmias History of cardiovascular disease or cerebral ischemic events Allergic reaction to any of the drug components Contraindication to tilt testing Any physical or psychological symptom, based on the clinical judgment of the investigators that would make a participant unsuitable for the study Any use of a medication(s) based on the clinical judgment of the investigators that would make a participant unsuitable for the study (e.g. fludrocortisone, theophylline, prazosin, doxazosin, terazosin, MAO-inhibitors, pseudoephedrine, decongestant and PDE5 inhibitors). Unwilling to discontinue Midodrine or beta-blocker therapy 48 hours before tilt table testing. Women who are pregnant (confirmed with pregnancy test on day of study) or lactating.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohamed H Hamdan, MD
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Wisconsin- Madsion
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
11194602
Citation
Bartoletti A, Alboni P, Ammirati F, Brignole M, Del Rosso A, Foglia Manzillo G, Menozzi C, Raviele A, Sutton R. 'The Italian Protocol': a simplified head-up tilt testing potentiated with oral nitroglycerin to assess patients with unexplained syncope. Europace. 2000 Oct;2(4):339-42. doi: 10.1053/eupc.2000.0125.
Results Reference
background

Learn more about this trial

The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope

We'll reach out to this number within 24 hrs